The future of obesity therapeutics is being written now – be a part of it! Visit the full agenda and speakers here: ...

Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer’s and analysts’ radar. On August 22, DBS Bank analyst Nico ...

The bankruptcy filing allowed WeightWatchers to cut its debt by $1bn without entirely wiping out existing shareholders: they ...

France's medicine safety agency has decided to broaden access to Wegovy and Mounjaro, which are not reimbursed by the French ...

Novo Nordisk (NVO) stock was down on Tuesday, despite a lack of news from the pharmaceutical company. Instead, investors can ...

Eli Lilly's Orforglipron helped patients with obesity and Type 2 diabetes lose over 10% body weight in phase 3 trials, ...

Elli Lily said on Tuesday that its daily weight loss pill helped patients lose weight, specifically those with obesity and ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

Novo Holdings, a leading healthcare investment firm, announced that it has signed a definitive agreement to successfully exit its investment in KabaFusion (the 'Company”). The transaction is subject ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Eli Lilly's GLP-1 pill, orforglipron, shows promising trial results for weight loss and type 2 diabetes. Global regulatory ...

Orforglipron will be submitted to global regulatory authorities for the treatment of obesity or for weight loss by the end of ...